

Living Cell Technologies Ltd

PO Box 3014, Auburn VIC 3123

ABN: 14 104 028 042

**Quarterly Cash Flow Report Period Ended 31 March 2007***ASX Announcement – 30 April 2007*

Attached is the Appendix 4C – Quarterly Cash Flow Report – for Living Cell Technologies (ASX:LCT) for the quarter ended 31 March 2007.

The cash balance at the end of the quarter was \$3,602,961 compared to \$896,334 at the end of the quarter to 31 December 2006.

The increase in available cash resulted from capital raisings during the quarter, with \$5,225,417 generated from issuing new shares. The majority of the capital raised was announced in February 2007, comprising \$3.0 million from a successful Share Purchase Plan and a \$1.3 million private placement. In addition in excess of \$800,000 was received in early January 2007 relating to a private placement announced in December 2006.

Net operating cash flows for the quarter to 31 March 2007 amounted to \$2,143,467, up from \$1,132,493 in the preceding quarter, an increase of \$1,010,974 in the period. This was largely attributable to an increase in working capital expenditure, which increased by \$791,365 from \$441,135 in the December quarter, to \$1,232,500 in the March quarter. Included in the working capital expenditure were a range of “one off” costs associated with the wind down of Living Cell Technologies Ltd’s North American operation, LCT BioPharma Inc, including final vacation leave entitlements and termination payments paid to US based staff.

In the quarter LCT has achieved a number of major milestones, the most notable being approval to start its diabetes cell transplant clinical trial. After a seven month strenuous international review, the New Zealand regulatory Medsafe has provided approval for LCT to proceed with its clinical trial application. LCT will now obtain ethics approval prior to beginning the trial before the end of the calendar year.

In addition, LCT has received regulatory and ethics approval to begin a Phase I/IIa clinical trial in Russia for its DiabeCell diabetes cell transplant. Patient recruitment has started and the first transplants are expected this coming month.

LCT has also recently announced the establishment of a Level 1 American Depository Receipt Program (ADR) under the Bank of New York. This program will assist in broadening and diversifying LCT’s shareholder base, by making it easier for US investors to access the stock, as well as increasing visibility of LCT in the international market.

The regulatory approvals provide a considerable validation for the Company’s capabilities. LCT is the only xeno cell transplant company to have met current regulatory guidelines of a high-health safe pig herd, GMP manufacturing and an audited diagnostic laboratory for monitoring of transplant recipients.

The first quarter for the calendar year has also seen LCT announce a new CEO – Dr Paul Tan, who has considerable experience in the production and development of products through clinical trials to commercialisation.

Further information: www.lctglobal.com		
Richard Justice Chief Financial Officer Mob: +64 27 222 3806	Paul Tan CEO Mob: +64 21 608 784	Paris Brooke General Manager - Australia Mob: +61 407 715 574

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

Living Cell Technologies Limited

ABN

14 104 028 042

Quarter ended ("current quarter")

31 March 2007

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A	Year to date (.6. months) \$A
1.1 Receipts from customers	128	592
1.2 Payments for		
(a) staff costs	(150,515)	(414,058)
(b) advertising and marketing	(5,433)	(12,788)
(c) research and development	(894,851)	(2,679,142)
(d) leased assets	0	0
(e) other working capital	(1,232,500)	(2,396,125)
1.3 Dividends received	0	402
1.4 Interest and other items of a similar nature received	24,988	66,528
1.5 Interest and other costs of finance paid	(16)	(154)
1.6 Income taxes paid	0	0
1.7 Other (Government Grants)	114,732	638,512
Net operating cash flows	(2,143,467)	(4,796,233)

+ See chapter 19 for defined terms.